Segall Bryant & Hamill LLC Grows Stock Holdings in PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Segall Bryant & Hamill LLC lifted its position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) by 18.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 168,882 shares of the company's stock after acquiring an additional 26,843 shares during the period. Segall Bryant & Hamill LLC owned 0.31% of PROCEPT BioRobotics worth $9,839,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PRCT. FMR LLC grew its stake in PROCEPT BioRobotics by 11.9% during the 4th quarter. FMR LLC now owns 8,159,208 shares of the company's stock worth $656,979,000 after buying an additional 866,328 shares during the last quarter. Vanguard Group Inc. increased its position in PROCEPT BioRobotics by 6.1% during the fourth quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock worth $413,907,000 after buying an additional 297,075 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of PROCEPT BioRobotics by 14.2% in the fourth quarter. Alliancebernstein L.P. now owns 1,752,478 shares of the company's stock valued at $141,110,000 after purchasing an additional 218,148 shares during the period. Wellington Management Group LLP boosted its holdings in PROCEPT BioRobotics by 38.8% in the fourth quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock valued at $120,051,000 after acquiring an additional 416,819 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of PROCEPT BioRobotics by 5.2% during the fourth quarter. Geode Capital Management LLC now owns 1,164,037 shares of the company's stock worth $93,751,000 after purchasing an additional 57,449 shares in the last quarter. Institutional investors and hedge funds own 89.46% of the company's stock.

Insider Activity

In related news, Director Antal Rohit Desai sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $61.49, for a total transaction of $1,537,250.00. Following the completion of the transaction, the director owned 14,363 shares of the company's stock, valued at approximately $883,180.87. The trade was a 63.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 100,000 shares of company stock valued at $6,271,250 over the last 90 days. Insiders own 17.40% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Morgan Stanley lowered their target price on PROCEPT BioRobotics from $71.00 to $68.00 and set an "overweight" rating for the company in a report on Tuesday, July 15th. Oppenheimer started coverage on PROCEPT BioRobotics in a report on Monday, July 7th. They issued a "market perform" rating for the company. Stephens started coverage on shares of PROCEPT BioRobotics in a research report on Wednesday, July 9th. They set an "overweight" rating and a $70.00 target price on the stock. Wall Street Zen downgraded shares of PROCEPT BioRobotics from a "hold" rating to a "sell" rating in a research report on Saturday, July 12th. Finally, Truist Financial lowered their target price on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, April 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $84.13.

PROCEPT BioRobotics Stock Down 2.2%

NASDAQ:PRCT traded down $1.30 on Monday, hitting $57.05. The company had a trading volume of 1,127,984 shares, compared to its average volume of 857,668. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.95 and a quick ratio of 7.75. The firm has a 50 day moving average of $58.73 and a two-hundred day moving average of $61.79. PROCEPT BioRobotics Corporation has a 52 week low of $47.04 and a 52 week high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.04. The business had revenue of $69.16 million during the quarter, compared to the consensus estimate of $65.39 million. PROCEPT BioRobotics had a negative net margin of 36.20% and a negative return on equity of 28.09%. PROCEPT BioRobotics's quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.51) earnings per share. As a group, sell-side analysts expect that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).